Ulcerative colitis and multiple sclerosis are two autoimmune conditions. People with ulcerative colitis may be at an increased risk of multiple sclerosis, but the opposite doesn’t seem to be true.

Pharmaceutical ads are difficult to avoid in American television programming and a growing number of them promote a class of ...

In a mid-stage study, the candidate itolizumab achieved 23.3% clinical remission rate at 12 weeks, numerically better than ...

PORTLAND, OR, UNITED STATES, February 7, 2025 /EINPresswire / -- The global ulcerative colitis (UC) market is ex ...

To present the pioneering concept, Peer and his team encoded the anti-inflammatory protein interleukin-10 into mRNA and ...

Bengaluru: Equillium, Inc., a clinical-stage biotechnology company and Biocon Limited, an innovation-led global ...

Equillium and Biocon announce positive data from phase 2 study of itolizumab to treat moderate to severe ulcerative colitis: Our Bureau, Bengaluru Friday, February 7, 2025, 10:30 ...

Resilience has characterized many people who have dealt with chronic health challenges, and it would be hard to find someone ...

A Feature on M&A, VC investment licensing and partnerships focusing on novel targets in autoimmune diseases.

SAN FRANCISCO -- Janus kinase (JAK) inhibitors appeared to be a safe, effective option for treating inflammatory bowel ...